| Birth | Immediate newborn protection where nationally recommended | Hepatitis B (many programmes); BCG where tuberculosis risk and policy support it | Protect newborns early against selected diseases present in the community or transmitted around birth | BCG is common in many countries but not routine in others (for example, most healthy US newborns). Hep B timing and dose count differ by programme |
|---|
| Early infancy (first weeks) | Start of the primary infant series in some schedules | First doses of combination vaccines (diphtheria–tetanus–pertussis containing), polio, Hib, pneumococcal, or rotavirus — depending on country | Build early immunity before peak exposure risk for several vaccine-preventable diseases | Some countries start at 6–8 weeks; others use a 2-month visit as the first major cluster. Exact antigens differ |
|---|
| Around 2 months | Primary series cluster in many national schedules | Diphtheria, tetanus, pertussis (DTaP/DTP/hexavalent combinations), polio (IPV/OPV), Hib, pneumococcal (PCV), rotavirus — commonly included in many programmes | Multiple primary doses establish protection against several serious bacterial and viral diseases of infancy | Visit timing may be labelled 8 weeks, 2 months, or similar. Combination products and brand names differ by country |
|---|
| Around 4 months | Continuation of primary infant doses | Additional doses of DTP/DTaP-containing vaccines, polio, Hib, PCV, and rotavirus where those series continue | Second (or next) primary doses improve and extend protection after the first visit | Interval rules and which vaccines share the same visit are set by each national programme |
|---|
| Around 6 months | Further primary doses; influenza eligibility in some countries | Third primary doses for several infant antigens in many schedules; influenza vaccine where recommended by age and season | Completing primary series doses reduces gaps in protection during the second half of infancy | Not every country schedules the same antigens at exactly 6 months. Influenza guidance is seasonal and age-dependent |
|---|
| 9–12 months | First measles-containing and other toddler vaccines | Measles-containing vaccine (measles alone or MMR/MMRV); other programme-specific vaccines may appear in this window | Maternal antibodies wane; measles vaccination timing balances early protection against circulating measles with immune response | WHO guidance often supports measles vaccination around 9 months in higher-risk settings; many low-risk programmes schedule MMR closer to 12 months |
|---|
| 12–18 months | Toddler boosters and first doses of additional antigens | MMR (if not given earlier), varicella, hepatitis A, Hib/PCV boosters, meningococcal vaccines — depending on national policy | Boosters and first doses for diseases that often appear in toddlerhood or preschool years | Varicella and Hep A are routine in some countries and optional/risk-based in others. Meningococcal products and ages differ widely |
|---|
| 18–24 months | Additional toddler doses or catch-up windows | Further doses of measles-containing, Hep A, or combination boosters where the national schedule places them | Complete multi-dose series and close immunity gaps before preschool | Some programmes concentrate visits earlier; others add an 18-month appointment. Always follow the local card |
|---|
| 4–6 years | School-entry / preschool boosters | DTaP/Tdap-containing boosters, polio boosters, second MMR (or measles-containing) dose — common in many schedules | Waning immunity and school/community exposure make booster timing important before school entry | Exact school-entry antigens and ages (4 vs 5–6 years) differ by country and region |
|---|
| Later childhood / adolescence | Adolescent platforms and catch-up | HPV, meningococcal vaccines, Tdap boosters, influenza; travel or outbreak vaccines as indicated | Protect against sexually transmitted vaccine-preventable disease (HPV), meningitis risk periods, and waning tetanus/pertussis immunity | Start ages for HPV and meningococcal programmes vary. Some vaccines remain risk-area or travel dependent |
|---|